4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000899243-16-028314
CIK 0001369786operating
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 6:25 PM ET
Size
9.6 KB
Accession
0000899243-16-028314
Insider Transaction Report
Form 4
OBERMAN ALLAN
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−9,459$205,733→ 92,527 total - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−92,527$2,012,462→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−108,696$776,089→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (108,696 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").
- [F2]Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Merger Consideration.
- [F3]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Aug 30, 8:00 PM ET
- Accepted
- Aug 31, 6:25 PM ET
- Size
- 9.6 KB